GPC2-CAR T cell therapy / Stanford University - LARVOL DELTA

Antigen Prescreening Enables Phase I Clinical Trial Enrollment for GPC2-CAR T Cell Therapy in Patients with Relapsed or Refractory CNS Embryonal Tumors (ISPNO 2026) - P1 | "These findings demonstrate feasibility of GPC2 antigen prescreening using archival tumor tissue to support early-phase trial enrollment, enabling coherent safety and early efficacy assessment of GPC2-CAR T-cells in pediatric CNS Embryonal tumors. Larger cohorts are needed to determine whether advanced scoring provides added benefit in borderline cases."

CAR T-Cell Therapy • Clinical • First-in-human • P1 data • Brain Cancer • CNS Tumor • Embryonal Tumor • Medulloblastoma • Oncology • Pineoblastoma • Rhabdoid Tumor • Sarcoma • Solid Tumor

Decoding the medulloblastoma surfaceome prioritizes the oncofetal antigen GPC2 for potent CAR-T cell therapy (AACR 2026) - P1 | "In a GPC2-low, GR3-MB model (HDMB03: ~3000 mol/cell) used to further dissect antigen detection limits, only cJUN.GPC2-CAR-T cells maintained anti-tumor responses. This work informed an ongoing phase-1 clinical trial at Stanford (NCT07087002), currently testing repeated, locoregional GPC2-CAR-T infusions and is planned to employ cJUN overexpression in patients with recurrent/refractory MB, aiming to provide a targeted treatment option for this devastating malignancy."

CAR T-Cell Therapy • IO biomarker • Brain Cancer • Diffuse Midline Glioma • Glioma • Medulloblastoma • Neuroblastoma • Oncology • Solid Tumor • MYC

GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Stanford University | Not yet recruiting ➔ Recruiting

Enrollment open • Brain Cancer • Embryonal Tumor • Medulloblastoma • Neuroblastoma • Oncology • Pediatrics • Pineoblastoma • Rhabdoid Tumor • Sarcoma • Solid Tumor